156 related articles for article (PubMed ID: 24461365)
21. JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.
Zhao X; Cai A; Peng Z; Liang W; Xi H; Li P; Chen G; Yu J; Chen L
J Cell Mol Med; 2019 Apr; 23(4):2489-2504. PubMed ID: 30672108
[TBL] [Abstract][Full Text] [Related]
22. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.
Liu J; Malavya S; Wang X; Saavedra JE; Keefer LK; Tokar E; Qu W; Waalkes MP; Shami PJ
Genomics; 2009 Jul; 94(1):32-8. PubMed ID: 19348908
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.
Chakrapani H; Goodblatt MM; Udupi V; Malaviya S; Shami PJ; Keefer LK; Saavedra JE
Bioorg Med Chem Lett; 2008 Feb; 18(3):950-3. PubMed ID: 18178089
[TBL] [Abstract][Full Text] [Related]
25. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
26. JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.
Tan G; Qiu M; Chen L; Zhang S; Ke L; Liu J
BMC Cancer; 2017 May; 17(1):376. PubMed ID: 28549433
[TBL] [Abstract][Full Text] [Related]
27. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
28. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Sunters A; Madureira PA; Pomeranz KM; Aubert M; Brosens JJ; Cook SJ; Burgering BM; Coombes RC; Lam EW
Cancer Res; 2006 Jan; 66(1):212-20. PubMed ID: 16397234
[TBL] [Abstract][Full Text] [Related]
30. JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.
Edes K; Cassidy P; Shami PJ; Moos PJ
PLoS One; 2010 Jan; 5(1):e8786. PubMed ID: 20098717
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme.
Günzle J; Osterberg N; Saavedra JE; Weyerbrock A
Cell Death Dis; 2016 Sep; 7(9):e2349. PubMed ID: 27584787
[TBL] [Abstract][Full Text] [Related]
32. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
33. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Kiziltepe T; Hideshima T; Ishitsuka K; Ocio EM; Raje N; Catley L; Li CQ; Trudel LJ; Yasui H; Vallet S; Kutok JL; Chauhan D; Mitsiades CS; Saavedra JE; Wogan GN; Keefer LK; Shami PJ; Anderson KC
Blood; 2007 Jul; 110(2):709-18. PubMed ID: 17384201
[TBL] [Abstract][Full Text] [Related]
34. O2-(2,4-dinitrophenyl) diazeniumdiolate derivative induces G2/M arrest via PTEN-mediated inhibition of PI3K/Akt pathway in hepatocellular carcinoma cells.
Liu L; Xu J; Zhai Z; Cao M; Huang Z; Xing Y; Chen J
J Pharm Pharmacol; 2021 Sep; 73(10):1330-1339. PubMed ID: 34190329
[TBL] [Abstract][Full Text] [Related]
35. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
36. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
37. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
[TBL] [Abstract][Full Text] [Related]
38. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
[TBL] [Abstract][Full Text] [Related]
39. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
40. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]